Skip to content
Nuclera logo — Bring rapid protein access to your benchtop with eProtein Di...

Nuclera

Bring rapid protein access to your benchtop with eProtein Discovery

Founded 2013 United Kingdom Cambridge, United Kingdom 108 employees Series C Total: $207.83M Biotechnology, Life Sciences +1

General Information

Company Name Nuclera
Founded Year 2013
Location United Kingdom Cambridge, United Kingdom
Founders / Decision Makers
Team member
Employees 108
Industries Biotechnology, Life Sciences, Pharmaceutical
Funding Stage Series C
Business Model B2B, SaaS, D2C
Revenue Model Product Sales, Usage Based, Service Fee
Offices as of Oct 2026
Cambridge, United Kingdom Billerica, United States
Social

BounceWatch is an independent company data service, not affiliated with Nuclera. To contact Nuclera, visit nuclera.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Nuclera compare?

A PDF of Nuclera and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Nuclera soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 10, 2026

Nuclera will be presenting data and talks at PEGS Europe 2026 at booth 313.

New Partnership Oct 28, 2026

Nuclera collaborated with Dima Chirgadze's lab at the Department of Biochemistry, University of Cambridge on a cell-free cryo-EM study.

Actively Hiring Oct 26, 2026

Hiring for 1 position in the last 30 days.

Major Customer Win Oct 21, 2026

Bayer Crop Science provided insights on how Nuclera's eProtein Discovery™ membrane protein workflow helped them recover difficult membrane protein targets.

AI Insight

Bounce Watch AI
1 week ago

Nuclera is undergoing a significant strategic shift, marked by the recent appointment of Carl Raimond as CEO in October 2026, signaling a potential new growth phase and operational focus. This leadership change coincides with strong market validation, evidenced by a major customer win with Bayer Crop Science and a strategic research collaboration with the University of Cambridge, underscoring the efficacy and scientific relevance of their eProtein Discovery™ system. These developments, coupled with media coverage on their growth strategy, suggest the company is poised for accelerated expansion and increased market penetration.

Signal Types
Leadership Change Customer Win Partnership Media Coverage
Strategic Labels
Leadership Transition Market Validation Strategic Partnerships
Next Move: Expansion
·
Impact: 9/10
·
Ideal For: Growth Equity VCs — Biotechnology

About Nuclera

Nuclera, founded in 2013 by PhD students at the University of Cambridge, has positioned itself as a transformative player in the biotechnology, life sciences, and pharmaceutical industries. With its headquarters in the United Kingdom and a burgeoning presence in Boston, MA, the company employs over 100 professionals dedicated to advancing protein science.

Capitalizing on its pioneering eProtein Discovery™ technology, Nuclera revolutionizes how researchers access and screen proteins through innovative, cell-free expression systems and digital microfluidics. This system enables rapid, in-house multiplex protein screening, even for challenging membrane proteins, which accelerates scientific discovery and breakthroughs in human health.

In its latest funding round on 01 January 2026, Nuclera secured a $12.00M Series C investment led by Elevage Medical Technologies, with participation from British Business Bank, Jonathan Milner, and GK Goh Financial Services. This investment underscores strong confidence in Nuclera's potential to make protein access routine and propel scientific innovation forward.

Business keywords: protein science, multiplex protein screening, cell-free expression systems, digital microfluidics, protein characterization, drug discovery, membrane proteins, biotech innovation, research acceleration, protein optimization, lab automation, protein synthesis, biotech startup, scientific research tools, rapid protein prototyping

Services & Products

eProtein Discovery System
Antibody Screening Services
Protein Design and Expression
Membrane Protein Production

Target Customers

Biotechnologists Pharmaceutical Researchers Drug Discovery Scientists Structural Biologists Academic Research Institutions

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $12.00M 4
Elevage Medical Technologies, British Business Bank +2
01 Jan 2026
Growth Equity VC £51.50M -
01 Oct 2025
Series C $75.00M 10
Verve Ventures, Cambridge Innovation Capital +8
01 Oct 2024
Grant £1.10M 1
Innovate UK
01 Jun 2024
Series B $15.50M 2
Verve Ventures, Jonathan Milner
01 Jul 2022
Series B $42.50M 7
Amadeus Capital Partners, Future Planet Capital +5
01 Feb 2022
Late VC $10.00M -
01 Dec 2018
Grant £200.00K -
01 Apr 2015
Grant £30.00K -
01 Jun 2014

Nuclera Alternatives & Competitors

View All Alternatives
Nuclera vs
Adaptyv
Adaptyv Switzerland

The cloud lab for protein designers

Series A
40 employees
Biotechnology, Pharmaceutical
Nuclera vs
LabFellows
LabFellows United States

Do More Science.

Seed
4 employees
Biotechnology, Life Sciences
Nuclera vs
AnaBios Corporation
AnaBios Corporation United States

The Power of the Human Model

Series C
38 employees
Biotechnology, Pharmaceutical

FAQ About Nuclera

Bring rapid protein access to your benchtop with eProtein Discovery
Nuclera was founded in 2013.
Nuclera is headquartered in Cambridge, United Kingdom. As of Oct 2026, it also has offices in Billerica, United States.
Nuclera operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on protein science, multiplex protein screening, cell-free expression systems and digital microfluidics. Its customers include Biotechnologists, Pharmaceutical Researchers and Drug Discovery Scientists.
Nuclera has a B2B, SaaS and D2C business model. Its revenue comes from Product Sales, Usage Based and Service Fee.
Nuclera has approximately 108 employees.
Nuclera has completed 9 funding rounds, raising a total of $207.83M. The latest funding stage is Series C.
Nuclera offers: eProtein Discovery System, Antibody Screening Services, Protein Design and Expression, Membrane Protein Production.
Top alternatives and competitors to Nuclera include Adaptyv, LabFellows, AnaBios Corporation, LabTwin, Future Fields. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Nuclera and Adaptyv are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Nuclera, https://www.bouncewatch.com/company/nuclera, updated 11 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout